Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

BmTI-A, a Kunitz type inhibitor from Rhipicephalus microplus able to interfere in vessel formation

Full text
Author(s):
Soares, Tatiane S. [1] ; Oliveira, Felipe [1] ; Torquato, Ricardo J. S. [1] ; Sasaki, Sergio D. [2] ; Araujo, Mariana S. [1] ; Paschoalin, Thaysa [3] ; Tanaka, Aparecida S. [1]
Total Authors: 7
Affiliation:
[1] Univ Fed Sao Paulo UNIFESP, Dept Biochem, Escola Paulista Med, Rua 3 Maio 100, BR-04044020 Sao Paulo, SP - Brazil
[2] Univ Fed ABC, Ctr Ciencias Nat & Humanas, Rua Catequese 242, BR-09090400 Santo Andre, SP - Brazil
[3] Univ Fed Sao Paulo UNIFESP, Dept Microbiol Immunol & Parasitol, Escola Paulista Med, BR-04023062 Sao Paulo, SP - Brazil
Total Affiliations: 3
Document type: Journal article
Source: Veterinary Parasitology; v. 219, p. 44-52, MAR 30 2016.
Web of Science Citations: 7
Abstract

Rhipicephalus microplus is an ectoparasite responsible for transmissions of babesiosis and anaplasmosis causing large losses to livestock production. To survive R. microplus tick produces several active molecules, such as protease inhibitors. This ectoparasite has been described as a rich source of serine protease inhibitors most of them are Kunitz-BPTI members named BmTIs which have no clear function yet. In the present work, we described the expression and functional characterization of rBmTI-A which showed to be similar to the native BmTI-A, a double-headed Kunitz-BPTI inhibitor, capable to inhibit trypsin, human neutrophil elastase (HNE), human plasma kalikrein (HuPK) and human plasmin. rBmTI-A was able to cause a decrease of HUVEC cell viability. Besides, the rBmTI-A showed to be a potent inhibitor of ``in vitro{''} vessel formation. Our results suggested that BmTI-A may participate in the blood acquisition process interfering in the vessel formation during the tick parasite life stage, around 20 days. In conclusion, BmTI-A is a promising molecule to be used in the drug design and development of new method of R. microplus control. (C) 2016 Elsevier B.V. All rights reserved. (AU)

FAPESP's process: 05/03514-9 - Studies of the physiological function and biotechnological potential of protease inhibitors and anti-hemostatics in hematophagous arthropods
Grantee:Aparecida Sadae Tanaka
Support Opportunities: Research Projects - Thematic Grants
FAPESP's process: 12/03657-8 - Inhibitor and proteases of ectoparasites: relationship of structure-function and identification of the role of these molecules in the interaction of diseases vector e their etiological agents
Grantee:Aparecida Sadae Tanaka
Support Opportunities: Research Projects - Thematic Grants